Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Biohaven's BHV-1300?
BHV-1300 is a small molecule commercialized by Biohaven, with a leading Phase I program in Rheumatoid Arthritis. According to Globaldata,...
BHV-1300 by Biohaven for Rheumatoid Arthritis: Likelihood of Approval
BHV-1300 is under clinical development by Biohaven and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Biohaven's BHV-1300?
BHV-1300 is a small molecule commercialized by Biohaven, with a leading Phase I program in Rheumatoid Arthritis. According to Globaldata,...